ACRS news

Aclaris Therapeutics entered into an underwriting agreement to sell shares and pre-funded warrants for an aggregate of 14.29 million securities, priced and time-to-market details not provided in the document.

Aclaris Therapeutics announced rapid and robust responses to its bispecific antibody ATI-052 in atopic dermatitis and asthma trials, with a favorable safety profile, strong clinical proof-of-concept, and plans to advance the candidate into Phase 2b development for eosinophilic esophagitis.

Aclaris Therapeutics announced full Phase 1a trial results for ATI-052 and affirmed timelines for upcoming clinical data readouts and a Phase 2b program.